Placebo + Omega-3 carboxylic acid + Fenofibrate 200mg + Placebo
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-alcoholic Fatty Liver Disease (NAFLD
Conditions
Non-alcoholic Fatty Liver Disease (NAFLD, Hypertriglyceridemia
Trial Timeline
Sep 1, 2015 → May 26, 2016
NCT ID
NCT02354976About Placebo + Omega-3 carboxylic acid + Fenofibrate 200mg + Placebo
Placebo + Omega-3 carboxylic acid + Fenofibrate 200mg + Placebo is a phase 2 stage product being developed by AstraZeneca for Non-alcoholic Fatty Liver Disease (NAFLD. The current trial status is completed. This product is registered under clinical trial identifier NCT02354976. Target conditions include Non-alcoholic Fatty Liver Disease (NAFLD, Hypertriglyceridemia.
What happened to similar drugs?
0 of 4 similar drugs in Non-alcoholic Fatty Liver Disease (NAFLD were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02354976 | Phase 2 | Completed |
Competing Products
20 competing products in Non-alcoholic Fatty Liver Disease (NAFLD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IVA337 + IVA337 + Placebo | Inventiva | Phase 2 | 29 |
| GODEX + Placebo | Celltrion | Phase 3 | 47 |
| ASP9831 + Placebo | Astellas Pharma | Phase 2 | 35 |
| AZD9550 + AZD9550 + Placebo | AstraZeneca | Phase 1 | 29 |
| AZD2693 | AstraZeneca | Phase 1 | 29 |
| placebo + Omega-3 carboxylic acids + Dapagliflozin + Placebo | AstraZeneca | Phase 2 | 35 |
| AZD4831 | AstraZeneca | Phase 2 | 35 |
| AZ compound | AstraZeneca | Phase 2 | 27 |
| cotadutide solution for injection | AstraZeneca | Phase 1 | 29 |
| Cotadutide + Cotadutide-placebo + Moxifloxacin + Moxifloxacin-placebo | AstraZeneca | Phase 1 | 21 |
| AZD4076 + Placebo | AstraZeneca | Phase 1 | 29 |
| Cotadutide + Placebo | AstraZeneca | Phase 2 | 35 |
| AZD7503 Intervention | AstraZeneca | Phase 1 | 29 |
| Efinopegdutide + Semaglutide + Placebo | Merck | Phase 2 | 35 |
| MK-4074 200 mg + Placebo for MK-4074 + Pioglitazone hydrochloride 30 mg + Placebo for pioglitazone hydrochloride | Merck | Phase 1 | 29 |
| Efinopegdutide | Merck | Phase 1 | 29 |
| LIK066 + Placebo | Novartis | Phase 2 | 35 |
| Tropifexor (LJN452) + Cenicriviroc (CVC) | Novartis | Phase 2 | 35 |
| LYS006 + Tropifexor | Novartis | Phase 2 | 27 |
| LMB763 + Placebo | Novartis | Phase 2 | 27 |